Therapeutic drug monitoring of flecainide in serum using high-performance liquid chromatography and electrospray mass spectrometry.
High-performance liquid chromatography with electrospray mass spectrometry (LC-MS) was used for analysis of the drug flecainide in serum. The clean-up was performed by solid-phase extraction, and an aromatic ring positional isomer was used as internal standard. Results from method validation on spiked serum samples showed excellent reproducibility; intra- and inter-assay variations (C.V.% and %Bias) were less than 6% within the therapeutic concentration range of the drug (0.2-1.0 microg/ml). Linearity was demonstrated from 0.05 to 2.0 microg/ml. The limit of detection and quantification was 0.025 and 0.05 microg/ml, respectively. Due to the high selectivity of the mass spectrometric detection, no interferences were observed. Results from clinical samples (n=18) from patients in treatment with Tambocor (flecainide acetate) showed excellent correlation with parallel data obtained from a method based on high-performance liquid chromatography (HPLC) with fluorescence detection after liquid/liquid extraction. The chromatographic separation of flecainide and internal standard was improved compared to earlier HPLC methods. The methodology is simple, accurate and requires only 0.25 ml of sample. It is a well suited method for routine therapeutic drug monitoring in a hospital or clinical chemistry laboratory.
Breindahl
T
T
Department of Clinical Chemistry, Hjørring/Brønderslev Hospital, Denmark. tob@dhi.dk
D000889:Anti-Arrhythmia Agents / Q000097:blood*; D001274:Atmospheric Pressure; D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D005424:Flecainide / Q000097:blood*; D006801:Humans; D015203:Reproducibility of Results; D021241:Spectrometry, Mass, Electrospray Ionization
D000889:Anti-Arrhythmia Agents; D005424:Flecainide